The National Academies’ Standing Committee on Use of Emerging Science for Environmental Health Decisions was established to facilitate communication among government, industry, environmental groups, and the academic community about scientific advances that may be used in the identification, quantification, and control of environmental impacts on human health.

The committee is composed of the following members:

William H. Farland (Chair)
Colorado State University

George P. Daston
Procter & Gamble Company

Richard A. Denison
Environmental Defense Fund

Carolyn Mattingly
Mount Desert Island Biological Lab

Ana Navas-Acien
Johns Hopkins University-Bloomberg School of Public Health

Chirag Patel
Harvard Medical School

Jason Richardson
Northeast Ohio Medical University

Ivan Rusyn
Texas A&M University

Joel Schwartz
Harvard School of Public Health

Joyce S. Tsuji
Exponent, Inc.

Cheryl Lyn Walker
Texas A&M Health Science Center

Helmut Zarbl
Robert Wood Johnson Medical School

Lauren Zeise
California Environmental Protection Agency

Committee Member Bios

William H. Farland (Chair), PhD, ATS, is the Senior Advisor to the Executive Vice President, Colorado State University and a professor in the Department of Environmental and Radiological Health Sciences, School of Veterinary Medicine and Biomedical Sciences. Formerly, Dr. Farland served as Vice President for Research from 10/2006-9/2013.  Dr. Farland holds a Ph.D. (1976) from UCLA in cell biology and biochemistry.  In 2006, Dr. Farland was appointed Deputy Assistant Administrator for Science in the U.S. Environmental Protection Agency’s Office of Research and Development (ORD).  He had served as the Acting Deputy Assistant Administrator since 2001.  In 2003, Dr. Farland was also appointed Chief Scientist in the Office of the Agency Science Advisor. He served as the EPA’s Acting Science Advisor throughout 2005. Prior to that, he was the Director of the ORD’s National Center for Environmental Assessment. Dr. Farland’s 27 year federal career was characterized by a commitment to the development of national and international approaches to the testing and assessment of the fate and effects of environmental agents.   Dr. Farland has continually served on a number of executive-level committees and advisory boards within the Federal government.   In 2005-2006, he chaired the Executive Committee of the National Toxicology Program (NTP).  He was also a member of the Scientific Advisory Council of the Risk Sciences and Public Policy Institute, Johns Hopkins University School of Hygiene and Public Health; a public member of the American Chemistry Council’s Strategic Science Team for its Long-Range Research Initiative, and a member of the Programme Advisory Committee for the WHO’s International Programme on Chemical Safety.  Dr. Farland served as Chair of an External Advisory Group for the National Institute of Environmental Health Sciences (NIEHS) regarding the future of the Superfund Basic Research Program.  In 2013, Dr. Farland was appointed to the Board on Environmental Studies and Toxicology (BEST) of National Research Council (NRC). He also chairs a standing committee on Emerging Science for Environmental Health Decisions of the NRC and was a member of a NRC Committee to Develop a Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials.  In 2002, Dr. Farland was recognized by the Society for Risk Analysis with the “Outstanding Risk Practitioner Award,” and in 2005 was appointed as a Fellow of the Society.  In 2006, he received a Presidential Rank Award for his service as a federal senior executive.  In 2007, he was elected as a Fellow, Academy of Toxicological Sciences. Dr. Farland continues to teach, publish and serve as a reviewer in environmental toxicology and risk assessment.

George P. Daston, PhD, has been employed at Procter & Gamble Company since 1985, where he is Victor Mills Society Research Fellow. Dr. Daston has spent his entire career in research to understand the effects of exogenous chemicals on biological systems, especially the developing embryo, fetus and child. His research interests include teratogenic mechanisms, in vitro methodologies, and risk assessment. He has published over 100 peer-reviewed articles, reviews and book chapters, and has edited three books. Dr. Daston’s professional activities include serving as Councilor of the Society of Toxicology (2001-03); President (1999-2000) of the Teratology Society; member of the National Academy of Sciences Board on Environmental Studies and Toxicology (1995-98); member of the EPA Board of Scientific Counselors (2002-08); member of the U.S. National Toxicology Program Board of Scientific Counselors (2003-06, Chair in 2006); member of the National Children’s Study Advisory Committee (2003-06); and member of EPA’s Endocrine Disrupter Screening and Testing Advisory Committee (EDSTAC). He has served on several NRC committees, including the Committee on Developmental Toxicology, Committee on Research Opportunities and Priorities for EPA, and the Subcommittee on Arsenic in Drinking Water. Dr. Daston has served on the organizing committees for numerous government and private sector-organized workshops on reproductive toxicity, risk assessment, and non-animal alternatives. He chaired NIEHS/ICCVAM working groups evaluating the state of validation of the Frog Embryo Teratogenesis Assay – Xenopus (FETAX) assay for teratogen screening and receptor binding and transcriptional activation assays for estrogens and androgens. Dr. Daston is Editor-in-Chief of Birth Defects Research: Developmental and Reproductive Toxicology. Dr. Daston is an Adjunct Professor in the Department of Pediatrics and Developmental Biology Program at the University of Cincinnati and Children’s Hospital Research Foundation. Dr. Daston received his Ph.D. from the University of Miami and post-doctoral training at the U.S. EPA’s laboratories in Research Triangle Park, North Carolina.

Richard A. Denison, PhD, is a lead senior scientist at the Environmental Defense Fund. Dr. Denison has 30 years of experience in the environmental arena, specializing in chemicals policy and hazard, exposure, and risk assessment and management for industrial chemicals and nanomaterials. Dr. Denison is a member of the National Academy of Sciences’ Standing Committee on Emerging Science for Environmental Health Decisions. Until recently, he was on the NAS Board on Environmental Studies and Toxicology and served on the Green Ribbon Science Panel for California’s Green Chemistry Initiative. Dr. Denison has testified before various Congressional committees on the need for fundamental reform of US policy toward industrial chemicals and on nanomaterial safety research needs. He served as a member of the National Academy of Sciences’ Committee to Develop a Research Strategy for Environmental, Health and Safety Aspects of Engineered Nanomaterials. Previously, Dr. Denison was an analyst and assistant project director in the Oceans and Environment Program, Office of Technology Assessment, United States Congress. Dr. Denison received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University.

Carolyn Mattingly, PhD, received a BA in Art History from Oberlin College. Following her liberal arts education, she attended Tulane University and received a PhD in molecular toxicology. As a graduate student, she investigated the effects of the ubiquitous environmental contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), on vertebrate development using zebrafish as model organism. She then pursued postdoctoral training at the Weill Medical College of Cornell University where she investigated the effects of retinoids on differentiation in prostate epithelial cells and mechanisms by which environmental chemicals, including AHR ligands, interfered with retinoid signaling. Since 2001, she has been an Investigator and Director of Bioinformatics at the Mount Desert Island Biological Laboratory (MDIBL) in Salisbury Cove, Maine. At MDIBL, Dr. Mattingly is involved in several collaborative research programs. First, she directs development of the publicly available Comparative Toxicogenomics Database (CTD), which aims to enhance understanding about the etiologies of environmentally influenced diseases. She also conducts a laboratory research program in which she is investigating the effects of low-level exposure to arsenic or TCDD on vertebrate development using zebrafish. Recent studies uncovered novel targets of these chemicals that make significant contributions to understanding the basis of consequent phenotypes.

Ana Navas-Acien, MD, PhD, is Assistant Professor in the Department of Environmental Health Sciences at Johns Hopkins Bloomberg School of Public Health. She is a physician-epidemiologist with a specialty in preventive medicine and public health, and a long-term interest in the health consequences of widespread environmental exposures. Based on an epidemiologic approach, her research investigates chronic health effects of arsenic, selenium, lead, cadmium, and other trace metals. Dr. Navas-Acien has served as an expert witness to the Baltimore City Council and she has served as a member of the 2010 National Toxicology Program Workshop on the Role of Environmental Chemicals in the Development of Diabetes and Obesity. She earned an MD from the University of Granada School of Medicine in Spain and a PhD in epidemiology from Johns Hopkins School of Public Health.

Chirag Patel, PhD, is Associate Professor at Harvard Medical School. His research group aims to solve problems in human health and disease by developing bioinformatics approaches to reason over large-scale environmental exposure and genomic information spanning molecules to populations. Dr. Patel received his PhD in electrical engineering from Stanford University.

Jason Richardson, MS, PhD, DABT, is Professor of Pharmaceutical Sciences and Director of the Neurodegenerative Disease Research Focus Area at the Northeast Ohio Medical University. Previously, Dr. Richardson was tenured Associate Professor and Board Certified Toxicologist in the Department of Environmental and Occupational Medicine at Rutgers Robert Wood Johnson Medical School and Resident Member of the Environmental and Occupational Health Sciences Institute. He received his M.S. (1999) and Ph.D. (2002) degrees from Mississippi State University where he conducted research on mixtures of organophosphate pesticides and the developmental neurotoxicity of organophosphates. He then completed postdoctoral training in Molecular Neuroscience at Emory University (2002-2005) where he focused on the role of pesticide exposure in Parkinson’s disease. His research at EOHSI focuses on the role of environmental exposures and their interactions with genetic susceptibility as contributors to neurological disease using translational approaches. Dr. Richardson has authored or co-authored over 60 publications that have been cited over 2,000 times in the areas of developmental neurotoxicology, neurodegenerative disease, and pesticides. He has received the Outstanding New Environmental Scientist Award from the National Institute of Environmental Health Sciences and a Young Scientist Award from the American Society for Pharmacology and Experimental Therapeutics. Dr. Richardson is currently a member of the Editorial boards of Toxicological Sciences and Neurotoxicology, Neurotoxicology and Teratology, and was an Associate Editor for BMC Neurology. He has served as a grant reviewer for several NIH panels, the Michael J. Fox Foundation for Parkinson’s Disease Research, Health Canada, and the United Kingdom Parkinson’s Disease Society. He also served the Society of Toxicology as Secretary/Treasurer of the Neurotoxicology Specialty Section for two years.

Ivan Rusyn, MD, PhD, is Professor in the Department of Veterinary Integrative Biosciences in the College of Veterinary Medicine and Biomedical Sciences at Texas A&M University. Prior to joining Texas A&M University, Dr. Rusyn was professor of Environmental Sciences and Engineering at the University of North Carolina at Chapel Hill. Dr. Rusyn’s laboratory has an active research portfolio with a focus on the mechanisms of chemical toxicity, the genetic determinants of the susceptibility to toxicant-induced disease, and computational toxicology. His studies on health effects of chemical agents resulted in over 150 peer-reviewed publications. He has served on several US National Academies of Sciences/National Research Council committees and is currently a member of the Committee on Emerging Science for Environmental Health Decisions, Committee on Toxicology, and Committee on Incorporating 21st Century Science in Risk-Based Evaluations. He participated in WHO/IARC monographs 96, 100, 101, and 106, and chaired the overall Monograph 110, as well as chaired “Mechanistic and Other Relevant Evidence” sub-group for Monographs 101, 106, and 112. He is also serving on the Science Advisory Board for the North Carolina Department of Environment and Natural Resources. Dr. Rusyn received his MD from Ukrainian State Medical University in Kiev and his PhD in toxicology from the University of North Carolina-Chapel Hill.

Joel Schwartz, PhD, is a Professor of Environmental Epidemiology at the Harvard School of Public Health and Director of the Harvard Center for Risk Analysis. His work has been instrumental in the removal of lead from gasoline, and the setting of particulate air pollution standards around the world. Schwartz’s work tightened federal clean-air standards and improved compliance within industry. In addition to his research into lead, he was among the first to link elevated death rates to particulates of sulfur from coal-burning power plants and black carbon from motor-vehicle exhaust. Dr. Schwartz’s current research interests include health consequences of exposure to pollutants, health effects of ozone exposure, and effects of antioxidants on respiratory health. Dr. Schwartz received his Ph.D. from Brandeis University.

Joyce S. Tsuji, PhD, DABT, Fellow ATS, is a Principal Scientist within the Center for Toxicology and Mechanistic Biology of Exponent’s Health Sciences practice. She is a board-certified toxicologist and a Fellow of the Academy of Toxicological Sciences. Dr. Tsuji specializes in assessing exposure and risks associated with chemicals, and in communication of scientific issues. She has worked on projects in the United States and internationally for industry, trade associations, U.S. EPA and state agencies, the U.S. Department of Justice, the Australian EPA, municipalities, and private citizens. Dr. Tsuji’s experience includes human health and environmental toxicology related to a wide variety of chemicals in the environment as well as in products. She has designed and directed dietary and environmental exposure studies and community programs involving heatlh eeducation and biomonitoring for populations potentially exposed to chemicals in the environment, including soil, water, and food-chain exposures. She has also assessed exposure and health risks associated with chemical exposures from air, foods, medical devices, and a variety of consumer products (e.g., cleaners, air fresheners, cosmetics, paints and coatings, carpets, glues, wood preservatives, building materials, and children’s toys and play equipment), including those containing nonotechnology or nanomaterials. Dr. Tsuji has served on expert panels on toxicology and health risks issues for the National Academy of Sciences/National Research Council (including their Board on Environmental Studies and Toxicology and Committee on Toxicology), Institute of Medicine, and federal and state agencies.

Cheryl Lyn Walker, PhD, is Director of Texas A&M Health Science Center (TAMHSC) Institute of Biosciences and Technology in Houston and Welch Chair in Chemistry and a joint position as Clinical Professor in the College of Veterinary Medicine & Biomedical Sciences at Texas A&M University. Previously, Dr. Walker was Ruth and Walter Sterling Professor of Carcinogenesis at The University of Texas M.D. Anderson Cancer Center. She earned a Ph.D. in cell biology from Southwestern Medical School. Dr. Walker’s research interests include studying the genetic basis of susceptibility to cancer, specifically examining the interaction of carcinogens with genes during tumor development, characterizing the effects of endocrine disruptors on human health, and developing animal models for human disease. She also studies the molecular mechanisms of kidney, breast and uterine cancers and the effect of hormones of gene expression. She has served on the Board of Scientific Counselors of the National Cancer Institute and the NIEHS National Toxicology Program, and is a past President of the Society of Toxicology.

Helmut Zarbl, PhD, is Professor of Environmental and Occupational Medicine at the Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ). He is a member of the Environmental & Occupational Health Sciences  Institute (EOHSI), a joint Institute of UMDNJ and Rutgers, The State University of New Jersey. He is also the Director of the NIEHS Center for Environmental Exposures and Disease at EOHSI, is the Associate Director for Public Health Science at the Cancer Institute of New Jersey. Previously, he was a member of the Divisions of Human Biology and Public Health Sciences at the Fred Hutchinson Cancer Research Center (FHRCR), where he was Director and a Principal Investigator for the NIEHS sponsored FHFRC/University of Washington Toxicogenomics Research Consortium. Dr. Zarbl’s research has focused largely on toxicogenomics and functional genomics, carcinogenesis, molecular and cellular biology, and toxicology. Specifically this has included work to understand molecular mechanisms of chemical carcinogenesis, chemoprevntion, and the genetic basis for differential susceptibility to mammary carcinogenesis using both animal and in vitro model systems. Recent studies include the role of circadian rhythm in cancer risk and prevention. His studies in the area of toxicogenomics include the development and application of standards for DNA microarray experiments, and phenotypic anchoring of response of human cells, model organisms (yeast) and target organs (rodents) to toxicants, providing insights into dose and temporal responses, as well as mechanisms of action. Dr. Zarbl is also actively involved in technology development, including his patented work on RNAi and its application to the development of novel platforms for functional genomics (with Engineering Arts, Inc). Dr. Zarbl served on the NRC committee that produced Application of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment. Previously he was an Assistant and Associate Professor at M.I.T. He earned his Ph.D. in Biochemistry from McGill University.

Lauren Zeise, PhD, became acting director of OEHHA in May 2015. Dr. Zeise has been with OEHHA since its inception in 1991. She spent 3 years as Deputy Director for Scientific Affairs and 21 years as Chief of the Reproductive and Cancer Hazard Assessment Branch, which included managing the Proposition 65 program.  Prior to OEHHA’s creation, she was chief of the cancer unit at the California Department of Health Services and spent several years at the California Public Health Foundation and the U.S. Environmental Protection Agency. She played a leading role in OEHHA’s development of CalEnviroScreen, the nation’s first comprehensive statewide environmental health screening tool, which is used to identify the California communities most burdened by pollution from multiple sources and most vulnerable to its effects. She also co-led the team that developed the hazard trait regulation for California’s Safer Consumer Products program, and she has conducted hundreds of health risk assessments. Dr. Zeise earned her doctorate from Harvard University with a thesis on “Surrogate Measures of Human Cancer Risk.”  She has served on numerous national and international science advisory committees and boards focusing on environmental public health and improving the way chemicals are tested or evaluated for health risk. These include more than 20 National Academy of Sciences (NAS) committees, numerous U.S. Environmental Protection Agency panels, and advisory committees for the World Health Organization’s International Agency for Research on Cancer. She is a member, fellow, former editor, and former councilor of the Society for Risk Analysis and was the 2008 recipient of the Society’s Outstanding Risk Practitioner Award. She is also a member of the Society of Toxicology and an honorary lifetime NAS National Associate.